From: Prediction of health care expenditure increase: how does pharmacotherapy contribute?
All | Hospitalisation | No Hospitalisation | |||||
---|---|---|---|---|---|---|---|
N | P (Increase), % | N | P (Increase), % | N | P (Increase), % | ||
Total study population (irrespective of drug groups) | 373′264 | 51.9 | 66′427 | 23.1 | 306′837 | 58.1 | |
Patients with drug group and highest probability of increase in costs | |||||||
ATC | Name | N | P (Increase), % | N | P (Increase), % | N | P (Increase), % |
N06DA | Anticholinesterases | 2′214 | 61.1 | 587 | 43.4 | 1′627 | 67.4 |
N04BA | Dopa and dopa derivatives | 3′722 | 56.1 | 1′158 | 35.1 | 2′564 | 65.6 |
B01AA | Vitamin K antagonists | 18′893 | 51.6 | 6′087 | 27.0 | 12′806 | 63.2 |
B03BB | Folic acid and derivatives | 10′467 | 52.6 | 3′177 | 28.4 | 7′290 | 63.1 |
C01BD | Antiarrhythmics, class III | 4′622 | 47.3 | 1′890 | 25.7 | 2′732 | 62.3 |
C03CA | Sulfonamides, plain | 29′741 | 50.3 | 10′793 | 29.5 | 18′948 | 62.1 |
B03AD | Iron in combination with folic acid | 4′483 | 41.6 | 1′919 | 14.8 | 2′564 | 61.7 |
C03BA | Sulfonamides, plain | 3′256 | 52.7 | 961 | 31.2 | 2′295 | 61.7 |
G04CB | Testosterone-5a-reductase inhibitors | 2′238 | 53.2 | 552 | 27.5 | 1′686 | 61.6 |
A10BB | Sulfonylureas | 11′418 | 54.7 | 2′298 | 27.8 | 9′120 | 61.4 |
Patients with drug group and highest probability of decrease in costs | |||||||
ATC | Name | N | P (Decrease), % | N | P (Decrease), % | N | P (Decrease), % |
S01FA | Anticholinergics | 2′959 | 72.4 | 626 | 78.9 | 2′333 | 70.7 |
A03BA | Belladonna alkaloids, tertiary amines | 7′851 | 73.4 | 1′964 | 82.1 | 5′887 | 70.5 |
N01AH | Opioid anaesthetics | 9′715 | 72.3 | 2′235 | 81.9 | 7′480 | 69.5 |
S01HA | Local anaesthetics | 7′783 | 71.5 | 1′598 | 79.3 | 6′185 | 69.5 |
A04AA | Serotonin (5HT3) antagonists | 3′771 | 70.9 | 1′637 | 77.3 | 2′134 | 66.0 |
N01AX | Other general anaesthetics | 29′106 | 68.2 | 7′299 | 80.3 | 21′807 | 64.1 |
S01EC | Carbonic anhydrase inhibitors | 9′510 | 66.7 | 2′120 | 79.7 | 7′390 | 63.0 |
S01BC | Antiinflammatory agents, non-steroids | 13′218 | 65.3 | 2′935 | 77.9 | 10′283 | 61.7 |
C01CA | Adrenergic and dopaminergic agents | 13′690 | 65.3 | 3′085 | 79.7 | 10′605 | 61.2 |
A03BB | Belladonna alkaloids, semisynthetic | 7′718 | 66.1 | 2′089 | 80.7 | 5′629 | 60.8 |
Patients with drug group, high probability of decrease in costs and frequent prescriptions | |||||||
ATC | Name | N | P (Decrease), % | N | P (Decrease), % | N | P (Decrease), % |
B05BB | Solutions affecting the electrolyte balance | 66′792 | 64.0 | 20′392 | 77.9 | 46′400 | 58.0 |
V08AB | Low osmolar X-ray contrast media* | 29′654 | 63.7 | 10′870 | 78.1 | 18′784 | 55.3 |
S01CA | Corticosteroids and antiinfectives in combination | 28′050 | 59.7 | 5′774 | 78.0 | 22′276 | 55.0 |
N01BB | Amides | 57′144 | 59.6 | 14′887 | 77.0 | 42′257 | 53.5 |